WSW, NY, December 18th, 2025, FinanceWire
Nasus Pharma (NYSE: NSRX) has been initiated with coverage by Citizens, which assigned a ‘Market Outperform’ rating and a price target of $19 in a report dated December 18, 2025. As of the market close on December 17 2025, NSRX was trading at $6.5 per share.
Nasus Pharma is developing a dry powder intranasal delivery system aimed at transforming treatment in acute, life-threatening conditions where every minute matters.
The lead program, NS002, targets the $3 billion anaphylaxis treatment market by delivering epinephrine through a simple nasal spray rather than an auto-injector. Compliance with injectable devices has historically been low due to needle phobia, bulkiness, and user error in emergencies. Nasus’s powder spray is designed to overcome those barriers, potentially improving both speed of administration and patient adherence. Early studies suggest that NS002 may deliver epinephrine more rapidly to therapeutic blood levels than current injection-based standards.
Nasus’s approach is not limited to anaphylaxis. The same powder-based platform has already been applied to an intranasal naloxone product for opioid overdose reversal and to a COVID-19 antiviral spray, demonstrating versatility across therapeutic areas. This breadth creates multiple potential “shots on goal” for the company beyond its flagship allergy program.
The competitive landscape is also validating the concept. ARS Pharma’s Neffy, a liquid-based nasal epinephrine spray, received FDA approval in 2024 and has quickly gained market share, showing that regulators and patients are receptive to needle-free delivery. Nasus’s powder formulation may offer advantages in absorption speed, device usability, and stability compared to liquid sprays.
With a current market cap of around $60 million, Nasus is significantly smaller than peers already active in the space, yet it is targeting a large and growing global epinephrine market projected to reach $6–7 billion by 2030. Upcoming catalysts include further Phase 2 studies of NS002, where the company recently dosed its first patient, progress on manufacturing scale-up, and eventual regulatory milestones as the company moves toward more advanced stages.
Read this Next >> The Hidden Engine Behind Billion-Dollar Pharma Deals – And Why Nasus Pharma May Be Building One of Its Own
Recent News Highlights from Nasus:
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Nasus Pharma Ltd for promotional media services, which are provided on an ongoing basis. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. Market size figures or other estimates referenced in this article are quoted from publicly available sources; we do not independently verify or endorse them, and additional figures or estimates may exist. This article should not be considered an official communication of the issuer. The price target and rating in the report are those of Citizens and its analyst team, not of Nasus Pharma. The full report is available directly from Citizens representatives. The content beyond that is provided by the Author, wall street wire.